This page shows the latest RNA interference news and features for those working in and with pharma, biotech and healthcare.
Meanwhile, another non-clotting factor drug for haemophilia – Alnylam and Sanofi’s RNA interference candidate fitusiran – is also in late-stage development for haemophilia A and B.
Alnylam meanwhile says it is working with Vir Biotech on RNA interference drugs targeting ‘highly-conserved regions’ of COVID-19 RNA.
RNA interference (RNAi) drug lumasiran works upstream of the deficient enzyme, switching off production of a substrate that it converts to oxalate.
Alnylam has claimed a second US approval for one of its RNA interference (RNAi) drugs, getting an FDA nod for acute hepatic porphyria drug Givlaari.
It also said shifting the neuroscience projects to the US will make it easier for Lilly apply new technologies like RNA interference and gene therapy to the neuroscience projects.
Last December, the company reported disappointing results in a phase 2 trial of a RNA interference candidate called ARB-1467, handing a competitive advantage to Arrowhead Pharmaceuticals whose rival drug ... It has since abandoned the programme in favour
More from news
Approximately 1 fully matching, plus 42 partially matching documents found.
More than a decade of research into its RNA interference (RNAi) drugs generated the first ever approval of a drug in this category towards the end of 2018, and the company
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
These studies involve Silence's investigational portfolio of RNA interference (RNAi) therapeutics, which aim to treat conditions by selectively turning off genes expressed in an individual with a certain disease.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...